Correction to: Effectiveness and safety of sarilumab in patients with rheumatoid arthritis: A multicenter, retrospective, inverse probability of treatment-weighted analysis based on the FRAB-registry (Clinical Rheumatology, (2024), 43, 5, (1447-1459), 10.1007/s10067-023-06862-8)

The correct affiliation is presented in this article. In the original published version of the above article the affiliation for the co-author Takaaki Fukuda was incorrectly presented as "Department of Rheumatology, Rheumatology Center, 3-3-8 Miyanojin, Koga Hospital 21 Kurume City 839-0801, Japan". The affiliation has been corrected in this article. Also, the captions of Tables 2, 3, 4, and 5 were also incorrectly presented. The correct tables are shown as follows: (Table presented.) (Table presented.) (Table presented.) (Table presented.) Characteristics of patients in the groups with high or low BMI before and after IPTW-adjustment Factor Unadjusted p value IPTW-adjusted p value BMI<25 (n=72) BMI≥25 (n=35) BMI<25 (n=71) BMI≥25 (n=33.8) n (%) n (%) n (%) n (%) Age (years) 1 0.166 <65 27 (37.5) 13 (37.1) 25.4 (35.8) 7.3 (21.6) ≥65 45 (62.5) 22 (62.9) 45.6 (64.2) 26.5 (78.4) Sex 0.246 0.077 male 19 (26.4) 5 (14.3) 27.9 (39.3) 5.1 (15.1) female 53 (73.6) 30 (85.7) 43.1 (60.7) 28.7 (84.9) Weight (kg) <0.001 0.726 <57 50 (69.4) 4 (11.4) 36.4 (51.2) 15.5 (45.8) ≥57 22 (30.6) 31 (88.6) 34.6 (48.8) 18.3 (54.2) Steinbrocker class 0.384 0.196 1 / 2 67 (93.1) 30 (85.7) 67.2 (94.7) 29.1 (86.0) 3 / 4 5 ( 6.9) 5 (14.3) 3.8 ( 5.3) 4.7 (14.0) Steinbrocker stage 0.238 0.414 I / II 35 (48.6) 22 (62.9) 36.1 (50.9) 21.3 (63.0) III / IV 37 (51.4) 13 (37.1) 34.9 (49.1) 12.5 (37.0) CCI 0.998 0.689 0 54 (75.0) 27 (77.1) 54.5 (76.7) 27.4 (81.0) ≥1 18 (25.0) 8 (22.9) 16.5 (23.3) 6.4 (19.0) MTX 0.845 0.674 - 32 (44.4) 17 (48.6) 31.2 (43.9) 17.0 (50.1) + 40 (55.6) 18 (51.4) 39.8 (56.1) 16.9 (49.9) Failure of b/tsDMARDs 0.207 0.354 ≤1 43 (59.7) 26 (74.3) 43.8 (61.7) 25.3 (75.0) ≥2 29 (40.3) 9 (25.7) 27.2 (38.3) 8.5 (25.0) mean [range] mean [range] p value mean [range] mean [range] p value Duration of RA (years) 10.9 [0.2, 40.0] 10.6 [0.4, 35.8] 0.873 10.9 [0.2, 40.0] 10.1 [0.4, 35.8] 0.971 ACPA (U/mL) 209.6 [0.5, 1260.0] 256.0 [0.5, 1285.8] 0.745 216.9 [0.5, 1260.0] 229.8 [0.5, 1285.8] 0.902 RF (IU/mL) 183.9 [4.0, 1920.0] 114.9 [4.0, 769.0] 0.623 175.0 [4.0, 1920.0] 106.1 [4.0, 769.0] 0.831 TJC 3.6 [0.0, 19.0] 3.0 [0.0, 12.0] 0.677 3.2 [0.0, 19.0] 4.3 [0.0, 12.0] 0.299 SJC 3.0 [0.0, 16.0] 1.3 [0.0, 12.0] 0.002 2.5 [0.0, 16.0] 2.5 [0.0, 12.0] 0.867 PGA (mm) 45.0 [0.0, 99.0] 34.7 [3.0, 90.0] 0.051 43.0 [0.0, 99.0] 37.6 [3.0, 90.0] 0.406 EGA (mm) 41.2 [7.0, 88.0] 32.9 [2.0, 90.0] 0.053 39.8 [7.0, 88.0] 38.3 [2.0, 90.0] 0.902 CDAI 15.3 [1.0, 46.7] 11.1 [1.3, 36.0] 0.032 14.0 [1.0, 46.7] 14.3 [1.3, 36.0] 0.827 CRP (mg/dL) 1.82 [0.00, 8.51] 1.68 [0.02, 9.26] 0.852 1.78 [0.00, 8.51] 1.86 [0.02, 9.26] 0.327 WBC 7278.8 [2000.0, 17500.0] 8298.0 [4900.0, 13910.0] 0.058 7280.6 [2000.0, 17500.0] 7819.8 [4900.0, 13910.0] 0.508 Hb (g/dL) 12.4 [9.1, 17.4] 12.6 [9.4, 15.4] 0.395 12.6 [9.1, 17.4] 12.3 [9.4, 15.4] 0.965 Plt 26.0 [6.7, 49.6] 27.0 [15.5, 43.1] 0.528 25.4 [6.7, 49.6] 27.6 [15.5, 43.1] 0.11 ALT (U/L) 18.9 [6.0, 58.0] 22.7 [7.0, 77.0] 0.049 19.1 [6.0, 58.0] 18.3 [7.0, 77.0] 0.828 AST (U/L) 22.8 [10.0, 51.0] 21.7 [12.0, 46.0] 0.464 23.3 [10.0, 51.0] 20.7 [12.0, 46.0] 0.321 eGFR (mL/min/1.73 m²) 71.8 [6.2, 229.0] 66.3 [27.0, 104.0] 0.313 73.6 [6.2, 229.0] 64.9 [27.0, 104.0] 0.19 csDMARD except MTX 0.5 [0.0, 2.0] 0.6 [0.0, 2.0] 0.512 0.5 [0.0, 2.0] 0.7 [0.0, 2.0] 0.283 Dose of PSL (mg/day) 2.5 [0.0, 12.5] 3.4 [0.0, 12.0] 0.267 2.1 [0.0, 12.5] 2.8 [0.0, 12.0] 0.714 IPTW inverse probability of treatment weighting, MTX methotrexate, BMI body mass index, CCI Charlson comorbidity index, b/tsDMARD biologic or target synthetic disease-modifying anti-rheumatic drugs, ACPA anticitrullinated protein/peptide antibody, RF rheumatoid factor, TJC tender Joint count, SJC swollen joint count, PGA patient`s global assessment, EGA evaluator`s global assessment, CDAI clinical disease activity index, CRP C-reactive protein, WBC white blood cell, Hb hemoglobin, Plt platelet, ALT alanine aminotransferase, AST aspartate aminotransferase, csDMARD conventional synthetic disease modifying anti-rheumatic drug, PSL prednisolone Characteristics of patients in the groups with CCI score 0 or ≥1 before and after IPTW-adjustment Factor Unadjuste p value IPTW-adjusted p value CCI- (n=81) CCI+ (n=26) CCI- (n=80.6) CCI+ (n=27) n (%) n (%) n (%) n (%) Age (years) 0.015 0.832 <65 36 (44.4) 4 (15.4) 30.3 (37.6) 11.0 (40.8) ≥65 45 (55.6) 22 (84.6) 50.3 (62.4) 16.0 (59.2) Sex 0.718 0.578 male 17 (21.0) 7 (26.9) 17.4 (21.5) 4.5 (16.6) female 64 (79.0) 19 (73.1) 63.3 (78.5) 22.6 (83.4) Weight (kg) 1 0.382 <57 41 (50.6) 13 (50.0) 42.8 (53.0) 11.1 (41.1) ≥57 40 (49.4) 13 (50.0) 37.9 (47.0) 15.9 (58.9) BMI (kg/m²) 0.998 0.309 <25 54 (66.7) 18 (69.2) 54.0 (66.9) 14.2 (52.5) ≥25 27 (33.3) 8 (30.8) 26.7 (33.1) 12.8 (47.5) Steinbrocker class 0.407 0.841 1 / 2 75 (92.6) 22 (84.6) 74.6 (92.5) 24.7 (91.4) 3 / 4 6 ( 7.4) 4 (15.4) 6.1 ( 7.5) 2.3 ( 8.6) Steinbrocker stage 0.049 0.741 I / II 48 (59.3) 9 (34.6) 43.5 (53.9) 15.8 (58.4) III / IV 33 (40.7) 17 (65.4) 37.2 (46.1) 11.3 (41.6) MTX 0.471 0.808 - 35 (43.2) 14 (53.8) 36.6 (45.4) 11.4 (42.1) + 46 (56.8) 12 (46.2) 44.0 (54.6) 15.7 (57.9) Failure of b/tsDMARDs 1 0.793 ≤1 52 (64.2) 17 (65.4) 50.8 (63.0) 16.0 (59.3) ≥2 29 (35.8) 9 (34.6) 29.8 (37.0) 11.0 (40.7) mean [range] mean [range] p value mean [range] mean [range] p value Duration of RA (years) 10.2 [0.2, 37.8] 12.6 [0.4, 40.0] 0.282 10.6 [0.2, 37.8] 8.8 [0.4, 40.0] 0.323 ACPA (U/mL) 224.3 [0.5, 1285.8] 226.2 [0.6, 1200.0] 0.808 221.6 [0.5, 1285.8] 209.4 [0.6, 1200.0] 0.973 RF (IU/mL) 144.8 [4.0, 1440.0] 212.6 [4.0, 1920.0] 0.769 148.7 [4.0, 1440.0] 143.3 [4.0, 1920.0] 0.565 TJC 3.3 [0.0, 19.0] 3.7 [0.0, 13.0] 0.277 3.5 [0.0, 19.0] 3.8 [0.0, 13.0] 0.238 SJC 2.2 [0.0, 16.0] 3.2 [0.0, 10.0] 0.09 2.3 [0.0, 16.0] 2.3 [0.0, 10.0] 0.948 PGA (mm) 39.9 [0.0, 99.0] 47.0 [13.0, 90.0] 0.115 40.9 [0.0, 99.0] 43.4 [13.0, 90.0] 0.21 EGA (mm) 37.5 [2.0, 90.0] 41.7 [15.0, 80.0] 0.177 38.8 [2.0, 90.0] 39.8 [15.0, 80.0] 0.345 CDAI 13.3 [1.0, 46.7] 15.8 [6.0, 32.5] 0.043 11.5 [1.0, 46.7] 13.5 [6.0, 32.5] 0.133 CRP (mg/dL) 1.63 [0.00, 9.26] 2.22 [0.01, 6.00] 0.225 1.65 [0.00, 9.26] 1.69 [0.01, 6.00] 0.981 WBC 7600.1 [2000.0, 17500.0] 7649.6 [2860.0, 11400.0] 0.603 7601.4 [2000.0, 17500.0] 7578.4 [2860.0, 11400.0] 0.784 Hb (g/dL) 12.6 [9.5, 17.4] 12.1 [9.1, 14.4] 0.504 12.5 [9.5, 17.4] 12.1 [9.1, 14.4] 0.719 Plt 26.0 [6.7, 49.6] 27.3 [13.5, 43.2] 0.461 25.7 [6.7, 49.6] 29.2 [13.5, 43.2] 0.219 ALT (U/L) 20.9 [6.0, 77.0] 17.7 [7.0, 49.0] 0.245 20.9 [6.0, 77.0] 18.2 [7.0, 49.0] 0.483 AST (U/L) 22.5 [10.0, 48.0] 22.4 [12.0, 51.0] 0.841 22.9 [10.0, 48.0] 20.2 [12.0, 51.0] 0.265 eGFR (mL/min/1.73 m²) 72.1 [25.0, 229.0] 63.5 [6.2, 114.2] 0.204 70.2 [25.0, 229.0] 74.0 [6.2, 114.2] 0.496 csDMARD except MTX 0.5 [0.0, 2.0] 0.5 [0.0, 2.0] 0.967 0.5 [0.0, 2.0] 0.4 [0.0, 2.0] 0.159 Dose of PSL (mg/day) 2.8 [0.0, 12.5] 2.8 [0.0, 8.0] 0.54 2.9 [0.0, 12.5] 2.4 [0.0, 8.0] 0.787 IPTW inverse probability of treatment weighting, CCI Charlson comorbidity index, BMI body mass index, MTX methotrexate, b/tsDMARD biologic or target synthetic disease-modifying anti-rheumatic drugs, ACPA anticitrullinated protein/peptide antibody, RF rheumatoid factor, TJC tender joint count, SJC swollen joint count, PGA patient’s global assessment, EGA evaluator’s global assessment, CDAI clinical disease activity index, CRP C-reactive protein, WBC white blood cell, Hb hemoglobin, Plt platelet, ALT alanine aminotransferase, AST aspartate aminotransferase, eGFR estimated glomerular filtration rate, csDMARD conventional synthetic diseasemodifying anti-rheumatic drug, PSL prednisolone Characteristics of patients in the two groups with or without MTX before and after IPTW-adjustment Factor Unadjuste p value IPTW-adjusted p value MTXー (n=49) MTX+ (n=58) MTXー (n=49.2) MTX+ (n=57.7) n (%) n (%) n (%) n (%) Age (years) 0.02 0.966 <65 12 (24.5) 28 (48.3) 18.6 (37.7) 21.5 (37.3) ≥65 37 (75.5) 30 (51.7) 30.6 (62.3) 36.2 (62.7) Sex 0.243 0.794 male 14 (28.6) 10 (17.2) 11.2 (22.7) 11.8 (20.4) female 35 (71.4) 48 (82.8) 38.0 (77.3) 45.9 (79.6) Weight (kg) 0.765 0.883 <57 26 (53.1) 28 (48.3) 25.2 (51.2) 28.7 (49.6) ≥57 23 (46.9) 30 (51.7) 24.0 (48.8) 29.1 (50.4) BMI (kg/m²) 0.845 0.59 <25 32 (65.3) 40 (69.0) 32.0 (65.1) 40.6 (70.4) ≥25 17 (34.7) 18 (31.0) 17.2 (34.9) 17.1 (29.6) Steinbrocker class 0.2 0.168 1 / 2 42 (85.7) 55 (94.8) 43.0 (87.4) 54.8 (94.9) 3 / 4 7 (14.3) 3 ( 5.2) 6.2 (12.6) 3.0 ( 5.1) Steinbrocker stage 0.073 0.109 I / II 21 (42.9) 36 (62.1) 21.5 (43.7) 35.0 (60.7) III / IV 28 (57.1) 22 (37.9) 27.7 (56.3) 22.7 (39.3) CCI 0.471 0.857 0 35 (71.4) 46 (79.3) 37.4 (76.0) 44.8 (77.6) ≥1 14 (28.6) 12 (20.7) 11.8 (24.0) 12.9 (22.4) Failure of b/tsDMARDs 0.968 0.273 ≤1 31 (63.3) 38 (65.5) 28.1 (57.1) 39.4 (68.2) ≥2 18 (36.7) 20 (34.5) 21.1 (42.9) 18.4 (31.8) mean [range] mean [range] p value mean [range] mean [range] p value Duration of RA (years) 11.8 [0.2, 37.8] 10.0 [0.4, 40.0] 0.213 12.4 [0.2, 37.8] 10.9 [0.4, 40.0] 0.393 ACPA (U/mL) 210.6 [0.5, 1260.0] 236.7 [0.5, 1285.8] 0.632 188.7 [0.5, 1260.0] 245.4 [0.5, 1285.8] 0.992 RF (IU/mL) 197.3 [4.0, 1920.0] 130.9 [4.0, 1440.0] 0.766 179.6 [4.0, 1920.0] 127.9 [4.0, 1440.0] 0.827 TJC 3.4 [0.0, 19.0] 3.5 [0.0, 16.0] 0.164 3.6 [0.0, 19.0] 3.6 [0.0, 16.0] 0.255 SJC 2.7 [0.0, 16.0] 2.3 [0.0, 10.0] 0.664 2.6 [0.0, 16.0] 2.3 [0.0, 10.0] 0.37 PGA (mm) 40.3 [0.0, 99.0] 42.7 [3.0, 98.0] 0.428 42.9 [0.0, 99.0] 44.2 [3.0, 98.0] 0.574 EGA (mm) 37.7 [6.0, 90.0] 39.2 [2.0, 88.0] 0.651 36.5 [6.0, 90.0] 41.1 [2.0, 88.0] 0.213 CDAI 13.8 [1.0, 46.7] 13.9 [2.0, 34.0] 0.348 14.1 [1.0, 46.7] 14.4 [2.0, 34.0] 0.229 CRP (mg/dL) 1.79 [0.00, 7.49] 1.76 [0.00, 9.26] 0.757 1.50 [0.00, 7.49] 1.82 [0.00, 9.26] 0.702 WBC 7420.6 [2860.0, 12300.0] 7774.0 [2000.0, 17500.0] 0.646 7412.9 [2860.0, 12300.0] 7748.6 [2000.0, 17500.0] 0.673 Hb (g/dL) 12.3 [9.1, 17.4] 12.6 [9.4, 16.9] 0.261 12.4 [9.1, 17.4] 12.5 [9.4, 16.9] 0.555 Plt 24.9 [13.1, 38.3] 27.6 [6.7, 49.6] 0.19 25.0 [13.1, 38.3] 26.9 [6.7, 49.6] 0.361 ALT (U/L) 18.3 [6.0, 77.0] 21.7 [6.0, 58.0] 0.023 20.4 [6.0, 77.0] 20.2 [6.0, 58.0] 0.517 AST (U/L) 21.9 [11.0, 46.0] 22.9 [10.0, 51.0] 0.443 22.4 [11.0, 46.0] 23.0 [10.0, 51.0] 0.633 csDMARD except MTX 0.7 [0.0, 2.0] 0.3 [0.0, 2.0] 0.012 0.5 [0.0, 2.0] 0.5 [0.0, 2.0] 0.882 Dose of PSL (mg/day) 3.2 [0.0, 12.5] 2.4 [0.0, 10.0] 0.22 3.1 [0.0, 12.5] 2.5 [0.0, 10.0] 0.341 IPTW inverse probability of treatment weighting, MTX methotrexate, BMI body mass index, CCI Charlson comorbidity index, b/tsDMARD biologic or target synthetic disease-modifying anti-rheumatic drugs, ACPA anticitrullinated protein/peptide antibody, RF rheumatoid factor, TJC tender Joint count, SJC swollen joint count, PGA patient`s global assessment, EGA evaluator`s global assessment, CDAI clinical disease activity index, CRP C-reactive protein, WBC white blood cell, Hb hemoglobin, Plt platelet, ALT alanine aminotransferase, AST aspartate aminotransferase, csDMARD conventional synthetic disease modifying anti-rheumatic drug, PSL prednisolone Characteristics of patients in the two groups with prior b/tsDMARDs ≤1 or ≥2 before and after IPTW-adjustment Factor Unadjusted p value IPTW-adjusted p value Failure of b/ts DMARD ≤ 1 (n=69) ≥ 2 (n=38) failure of b/ts DMARD ≤ 1 (n=69) ≥ 2 (n=37.3) n (%) n (%) n (%) n (%) Age (years) 0.589 0.836 <65 24 (34.8) 16 (42.1) 25.3 (36.6) 12.9 (34.5) ≥65 45 (65.2) 22 (57.9) 43.7 (63.4) 24.4 (65.5) Sex 0.62 0.94 male 17 (24.6) 7 (18.4) 15.1 (21.9) 8.4 (22.6) female 52 (75.4) 31 (81.6) 53.9 (78.1) 28.9 (77.4) Weight (kg) 0.593 0.724 <57 33 (47.8) 21 (55.3) 33.9 (49.1) 19.8 (53.0) ≥57 36 (52.2) 17 (44.7) 35.1 (50.9) 17.5 (47.0) BMI (kg/m²) 0.207 0.374 <25 43 (62.3) 29 (76.3) 43.8 (63.5) 27.2 (72.9) ≥25 26 (37.7) 9 (23.7) 25.2 (36.5) 10.1 (27.1) Steinbrocker class 0.466 0.179 1 / 2 61 (88.4) 36 (94.7) 61.4 (89.0) 35.9 (96.0) 3 / 4 8 (11.6) 2 ( 5.3) 7.6 (11.0) 1.5 ( 4.0) Steinbrocker stage 0.267 0.058 I / II 40 (58.0) 17 (44.7) 41.6 (60.4) 14.9 (40.0) III / IV 29 (42.0) 21 (55.3) 27.3 (39.6) 22.4 (60.0) CCI 1 0.954 0 52 (75.4) 29 (76.3) 51.5 (74.7) 28.1 (75.2) ≥1 17 (24.6) 9 (23.7) 17.5 (25.3) 9.3 (24.8) MTX 0.968 0.243 - 31 (44.9) 18 (47.4) 28.8 (41.8) 20.3 (54.3) + 38 (55.1) 20 (52.6) 40.2 (58.2) 17.1 (45.7) mean [range] mean [range] p.value mean [range] mean [range] p.value Duration of RA (years) 10.9 [0.2, 40.0] 10.6 [0.7, 37.8] 0.496 10.60 [0.18, 40.00] 11.50 [0.69, 37.83] 0.156 ACPA (U/mL) 252.8 [0.5, 1285.8] 173.7 [0.5, 807.1] 0.772 237.29 [0.50, 1285.80] 181.23 [0.50, 807.10] 0.806 RF (IU/mL) 122.6 [4.0, 798.0] 231.5 [4.0, 1920.0] 0.642 122.32 [4.00, 798.00] 297.82 [4.00, 1920.00] 0.608 TJC 3.5 [0.0, 19.0] 3.4 [0.0, 12.0] 0.374 3.96 [0.00, 19.00] 3.23 [0.00, 12.00] 0.915 SJC 2.5 [0.0, 16.0] 2.3 [0.0, 10.0] 0.327 2.67 [0.00, 16.00] 2.28 [0.00, 10.00] 0.495 PGA (mm) 38.2 [0.0, 99.0] 47.8 [0.0, 98.0] 0.065 41.50 [0.00, 99.00] 43.04 [0.00, 98.00] 0.784 EGA (mm) 38.0 [6.0, 88.0] 39.5 [2.0, 90.0] 0.847 39.80 [6.00, 88.00] 37.96 [2.00, 90.00] 0.675 CDAI 13.6 [1.0, 46.7] 14.4 [2.5, 29.2] 0.254 13.0 [1.00, 46.70] 10.9 [2.50, 29.20] 0.98 CRP (mg/dL) 1.78 [0.00, 9.26] 1.77 [0.00, 7.49] 0.667 1.83 [0.00, 9.26] 2.11 [0.00, 7.49] 0.89 WBC 7493.3 [2000.0, 13910.0] 7827.9 [3700.0, 17500.0] 0.628 7548.34 [2000.00, 13910.00] 7892.98 [3700.00, 17500.00] 0.579 Hb (g/dL) 12.4 [9.1, 17.4] 12.6 [9.4, 17.4] 0.927 12.37 [9.10, 17.40] 12.52 [9.40, 17.40] 0.893 Plt 26.9 [6.7, 49.6] 25.3 [13.1, 49.2] 0.108 27.39 [6.70, 49.60] 25.40 [13.10, 49.20] 0.096 ALT (U/L) 20.2 [7.0, 58.0] 20.0 [6.0, 77.0] 0.341 20.45 [7.00, 58.00] 20.69 [6.00, 77.00] 0.316 AST (U/L) 22.0 [11.0, 51.0] 23.2 [10.0, 48.0] 0.876 22.17 [11.00, 51.00] 23.90 [10.00, 48.00] 0.74 eGFR (mL/min/1.73 m²) 66.7 [25.0, 110.0] 76.1 [6.2, 229.0] 0.175 67.60 [25.00, 110.00] 71.46 [6.20, 229.00] 0.898 csDMARD except MTX 0.6 [0.0, 2.0] 0.3 [0.0, 2.0] 0.011 0.51 [0.00, 2.00] 0.47 [0.00, 2.00] 0.852 Dose of PSL (mg/day) 2.9 [0.0, 12.5] 2.5 [0.0, 10.0] 0.802 2.81 [0.00, 12.50] 2.27 [0.00, 10.00] 0.698 IPTW inverse probability of treatment weighting, b/tsDMARD biologic or target synthetic disease-modifying antirheumatic drugs, BMI body mass index, CCI Charlson comorbidity index, MTX methotrexate, ACPA anticitrullinated protein/peptide antibody, RF rheumatoid factor, TJC tender joint count, SJC swollen joint count, PGA patient’s global assessment, EGA evaluator’s global assessment, CDAI clinical disease activity index, CRP Creactive protein, WBC white blood cell, Hb hemoglobin, Plt platelet, ALT alanine aminotransferase, AST aspartate aminotransferase, eGFR estimated glomerular filtration rate, csDMARD conventional synthetic diseasemodifying anti-rheumatic drug, PSL prednisolone The original article has been corrected.